Chimerix (CMRX) Filings

SC14D9C

Written communication relating to third party tender offer

5 Mar 25

8-K

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

5 Mar 25

8-K

Other Events

3 Mar 25

8-K

Entry into a Material Definitive Agreement

30 Dec 24

8-K

Regulation FD Disclosure

10 Dec 24

8-K

Departure of Directors or Certain Officers

14 Nov 24

8-K

Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

7 Nov 24

S-8

Registration of securities for employees

13 Aug 24

8-K

Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update

13 Aug 24

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

3 Jul 24

8-K

Submission of Matters to a Vote of Security Holders

21 Jun 24

EFFECT

Notice of effectiveness

6 May 24

8-K

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

1 May 24

DEFA14A

Additional proxy soliciting materials

26 Apr 24

8-K

Chimerix Appoints Marc D. Kozin to Board of Directors

21 Mar 24

S-3

Shelf registration

29 Feb 24

8-K

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

29 Feb 24

8-K

Chimerix Appoints Lisa Decker to Board of Directors

29 Dec 23

8-K

Departure of Directors or Certain Officers

4 Dec 23

8-K

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

16 Nov 23

8-K

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

2 Nov 23

8-K

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

3 Aug 23

8-K

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

27 Jun 23

8-K

Submission of Matters to a Vote of Security Holders

12 Jun 23

8-K

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

4 May 23

DEFA14A

Additional proxy soliciting materials

28 Apr 23

DEF 14A

Definitive proxy

28 Apr 23

8-K

Regulation FD Disclosure

10 Mar 23

S-8

Registration of securities for employees

2 Mar 23

10-K

2022 FY

Annual report

2 Mar 23

8-K

Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

2 Mar 23

8-K

Regulation FD Disclosure

12 Jan 23

4

Allen S. Melemed

14 Feb 25

4

Michael T. Andriole

14 Feb 25

4

Michael Albert Alrutz

14 Feb 25

4

David Jakeman

14 Feb 25

4

Michelle LaSpaluto

14 Feb 25

144

Notice of proposed sale of securities

13 Feb 25

144

Notice of proposed sale of securities

13 Feb 25

144

Notice of proposed sale of securities

13 Feb 25

144

Notice of proposed sale of securities

13 Feb 25

144

Notice of proposed sale of securities

13 Feb 25

4

David Jakeman

31 Jan 25

4

Michelle LaSpaluto

31 Jan 25

4

Michael T. Andriole

31 Jan 25

144

Notice of proposed sale of securities

30 Jan 25

144

Notice of proposed sale of securities

30 Jan 25

144

Notice of proposed sale of securities

30 Jan 25

4

Michelle LaSpaluto

10 Jan 25

4

Allen S. Melemed

10 Jan 25

4

David Jakeman

10 Jan 25

4

Thomas J Riga

10 Jan 25

4

Michael Albert Alrutz

10 Jan 25

4

Michael T. Andriole

10 Jan 25

4

FRED A MIDDLETON

30 Oct 24

144

Notice of proposed sale of securities

9 Aug 24

4

Michael T. Andriole

9 Aug 24

4

Victoria Vakiener

21 Jun 24

4

Pratik S Multani

21 Jun 24

4

FRED A MIDDLETON

21 Jun 24

4

Robert J. Meyer

21 Jun 24

4

MARC D KOZIN

21 Jun 24

4

Lisa Lynn Decker

21 Jun 24

4

MARTHA J DEMSKI

21 Jun 24

4

Michael A. Sherman

21 Jun 24

4

MARC D KOZIN

21 Mar 24

3

MARC D KOZIN

21 Mar 24

4

Michael T. Andriole

16 Feb 24

4

Michelle LaSpaluto

16 Feb 24

4

David Jakeman

16 Feb 24

SC 13G/A

RA CAPITAL MANAGEMENT, L.P.

14 Feb 24

144

Notice of proposed sale of securities

14 Feb 24